It is often concluded that chemotherapy-induced peripheral neuropathy (CIPN) is nonresponsive to many medications with demonstrated efficacy in other chronic peripheral neuropathic pain conditions. This conclusion is based on the fact that most clinical trials of these medications in CIPN have failed to demonstrate a significant treatment effect. 4, 8, 11 One hypothesis to explain these results is that painful CIPN may have different pathophysiological mechanisms than other types of neuropathic pain. 13, 18 However, we identified only 7 published randomized clinical trials that tested the efficacy of treatments for sub-acute or chronic CIPN, and only 4 of those tested treatments with demonstrated efficacy in other neuropathic pain conditions. 8 Furthermore, as we describe in this review, the trials that have evaluated the efficacy of neuropathic pain treatments (eg, gabapentin, tricyclic antidepressants) for CIPN have typically not evaluated pain, but have used variable combinations of "general" peripheral neuropathy symptoms, including pain, dysesthesias, and paresthesias ( Table 1 ).
Primary objectives
To evaluate the analgesic effects of a treatment on painful chemotherapy-induced peripheral neuropathy (CIPN), pain must be evaluated separately from the other symptoms associated with neuropathy. The primary outcome measures used in the published CIPN trials often assessed general neuropathy symptoms in the same measure, rather than pain alone. The composite measures used in these trials included numeric rating scales (NRS) or visual analogue scales of some combination of pain, numbness, or tingling; the Eastern Cooperative Oncology Group neuropathy scale 14 ; the National Cancer Institute-Common Toxicity Criteria 20 ; and the sensory subscale of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-induced peripheral neuropathy-20. 15 Three of the 6 trials that failed to demonstrate a significant treatment effect on general neuropathy symptoms did not assess the effect of the treatment on pain separately. Of the 3 studies that assessed pain separately, 2 included a pain scale as 1 of the 2 measures that were declared primary (in both cases the second primary outcome was one of general neuropathy symptoms), and 1 assessed pain only as a secondary outcome. Furthermore, only 2 of the studies that investigated a treatment with known efficacy in other neuropathic pain conditions included pain as a separate outcome 17, 19 and one of those 19 found a significant treatment effect for duloxetine in patients with painful CIPN (Table 1) .
Importantly, the evidence supporting the efficacy of existing neuropathic pain treatments is based on trials that evaluated the pain associated with peripheral neuropathy conditions such as painful diabetic peripheral neuropathy and postherpetic neuralgia and not general neuropathy symptoms. Most available treatments for neuropathic pain, including those evaluated for efficacy in CIPN, are symptomatic pain treatments with no known diseasemodifying or symptomatic effects on nonpainful symptoms. Therefore, existing neuropathic pain treatments would not be predicted to improve nonpainful neuropathy symptoms. In fact, only one medication (ie, tafamidis) is approved for a peripheral neuropathy indication by the European Medicines Agency and this approval is specifically for transthyretin familial amyloid polyneuropathy. No medications are approved by the Food and Drug Administration for a peripheral neuropathy indication.
It is worth noting that the trial by Smith et al. 19 did demonstrate a treatment effect of duloxetine on a secondary outcome measure of peripheral neuropathy, the FACT/GOG-Ntx. 3 The FACT/ GOG-Ntx is a composite measure that includes assessments of pain, numbness, tingling, and other symptoms. These data suggest that duloxetine may have efficacy for general peripheral neuropathy symptoms associated with CIPN in addition to efficacy for pain; however, the effect of duloxetine could be explained by FACT/GOG-Ntx pain-related items. Additionally, given the important methodological differences among the CIPN trials, this apparent effect of duloxetine on general peripheral neuropathy symptoms in CIPN does not suggest that the other trials are truly negative for general neuropathy symptoms.
Inclusion criteria
To assess the effects of a treatment on pain, it is essential that all the patients included in a clinical trial have at least moderate pain. Enrolling patients with only mild pain can impair detection of treatment efficacy because of a "floor effect" (ie, an inability to observe a decrease in symptoms if the condition is already too mild at baseline). 6 For example, a pooled analysis of 3 trials of patients with painful diabetic peripheral neuropathy and a metaanalysis of neuropathic pain trials demonstrated that lower baseline pain scores were associated with decreased assay sensitivity (ie, ability to demonstrate a difference between groups in a clinical trial).
Only 1 of the CIPN trials used a minimum average pain score (ie, $4 of 10 on a NRS) as an inclusion criterion. 19 The other trials used either (1) "painful paresthesiae" with no minimum pain requirement specified 10 ; (2) either $4 of 10 for average pain NRS or $1 on the Eastern Cooperative Oncology Group neuropathy scale, which does not require pain 16, 17 ; or (3) $4 of 10 on an NRS for "pain, numbness, or tingling" 2,9,12 ( Table 1) .
Of the trials that did not require a minimum pain score for inclusion, and therefore may have included patients who had no pain, the mean baseline average pain scores ranged from 3.6 to 4.2. 16, 17 These mean average pain scores are low for analgesic trials, 6 as a mean baseline pain score of 6.0 of 10 was reported in a meta-analysis of 200 neuropathic pain trials. 7 Furthermore, the mean average pain scores in the only published CIPN trial that had a minimum pain requirement for inclusion were 6.1 and 5.6 in the active and placebo groups, respectively. 19 The trials of gabapentin 17 and lamotrigine 16 did use a 0 to 10 NRS for average pain as 1 of the 2 outcome measures that were declared to be primary (Table 1) . However, because eligible patients were not required to have a minimum pain level and the baseline average pain scores were low, the inability to detect a treatment effect could be because of a floor effect. One study did note that, "the subset of patients who had higher pain scores at baseline did not appear to have a preferential benefit with gabapentin when compared with those with lower baseline scores." 17 However, subgroup analyses like these are underpowered and a nonsignificant difference between groups should not be interpreted as compelling evidence for lack of treatment efficacy.
Chronicity of pain
Although both acute and chronic CIPN are major unmet treatment needs, they are different conditions for which treatments should typically be assessed in separate clinical trials with homogeneous populations. Three CIPN trials allowed enrollment of both patients who were still receiving neurotoxic chemotherapy and also those who had completed chemotherapy. 2, 16, 17 When evaluating analgesics known to be efficacious for chronic neuropathic pain of other etiologies, enrolling patients still receiving chemotherapy could decrease the ability of the trial to detect effects on chronic painful CIPN. The neuropathy symptoms that occur during chemotherapy, as well their pathophysiological mechanisms are likely to differ from the symptoms and mechanisms found in individuals who have completed chemotherapy and may not be responsive to treatments that are effective for chronic pain.
CIPN symptoms during chemotherapy are likely to be worsening over time because of higher cumulative dosages of chemotherapy and may also vary depending on the duration of time that has elapsed since the latest dose of chemotherapy. 1 Additionally, symptoms occurring during chemotherapy are more likely to naturally dissipate once chemotherapy is discontinued than are the symptoms experienced by chronic CIPN patients who discontinued chemotherapy at least several months before. 1 This unstable severity of neuropathy symptoms during chemotherapy and shortly after is likely to add variability to neuropathy outcome measures and could decrease assay sensitivity in trials that recruit CIPN patients while they are still receiving chemotherapy.
Conclusions
Only 4 of the 7 published clinical trials of patients with chronic CIPN evaluated treatments that are recommended as first-line treatments for neuropathic pain by the International Association for the Study of Pain, Neuropathic Pain Special Interest Group treatment guidelines 8 (ie, amitriptyline, duloxetine, gabapentin, and nortriptyline). Thus, only those 4 trials would be expected to demonstrate efficacy if chronic painful CIPN responds to the same treatments as other chronic neuropathic pain conditions. Furthermore, of these 4 trials, the one that successfully demonstrated the efficacy of the treatment on neuropathic pain (ie, duloxetine) was the only one that (1) used a primary outcome measure that assessed only pain, (2) used a minimum pain intensity for the principal inclusion criterion, and (3) included only patients who had completed chemotherapy. 19 It cannot be determined whether the other trials are falsely or truly negative for the treatment of peripheral neuropathy, but it is clear that they do not evaluate the efficacy of the treatments for neuropathic pain. Thus, it should not be concluded that painful CIPN is pathophysiologically different than other types of peripheral neuropathic pain based on the nonsignificant results of the published CIPN trials. Future trials that aim to assess symptomatic chronic pain treatments should use validated pain measures for the primary efficacy analysis (eg, 0-10 NRS daily diary for pain). 5 The pain measure should specify whether participants are to rate their worst or average pain and participants should be instructed to rate only the pain in their hands and/or feet that has developed since their chemotherapy was initiated. These trials should include only patients who have completed chemotherapy at least 3 months before enrollment and who meet a minimum baseline pain requirement (eg, $4 on a 0-10 NRS for average pain). 6 Additionally, a neurological examination is recommended to confirm that eligible participants have peripheral neuropathic pain associated with CIPN. Such trials must be conducted before chronic painful CIPN is declared refractory to current or future neuropathic pain treatments. 
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